Skip to content

About Event

With the recent progress of immunotherapy candidates entering clinical trials, preclinical oncology has undergone a revolution. The focus has steadily been shifting away from cytotoxic agents to immune-oncology and the potential of combination therapeutics, which poses novel challenges to the industry:

 

- What models should be used during the various stages of immuno-oncology preclinical development?
- Which are better suited for discovery and optimisation versus validation?
- How can 3D models improve in vivo outcomes to increase translational success?

 

The 8th Annual PREDiCT: Tumour Models Summit returns to London between 4-6 December to provide you with the insight of latest progress in preclinical oncology modelling.

Moving beyond efficacy, we will focus on advancing preclinical models with I/O therapeutics by gaining a better understanding of immune response and novel tumour-immune cell interactions – increasing your predictability and translatability of combination therapy success in clinical trials. 

 

Here is a Selection of Companies You Will Hear From:

  • MedImmune
  • Roche
  • Sanofi
  • Kymab
  • Merck
  • Gustave Rousy Institut
  • AstraZeneca
  • National Centre for Tumor Diseases
  • CIPHE-INSERM
  • Basilea Pharmaceutica

 

Over 3 days, this will be your opportunity to network with 100+ world leading experts and apply the latest case study evidence to tackle key challenges including tumour resistance, adaptive microenvironment and metastasis – helping you validate your tumour model selection strategy and translational confidence.